Next Investors logo grey

I’m dreaming of a genome Christmas

Published 29-JAN-2019 10:38 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Recently in Melbourne it was 44 degrees. It was hot. Damn hot. Real hot. Hottest things is my shorts. I could cook things in it. Thanks to the late, great Robin Williams for that. It was hot around the country and some people who forgot to slip, slop, slap were getting burnt to a crisp.

This brings me to the completely unrelated CRISPR.

CRISPR-Cas9 is a gene editing tool that makes it easier to edit the genome. It has become so popular amongst the research and development set that companies such as the German chemical producer BASF are exploring its potential in commercial agriculture and microbiology.

You can read more about CRISPR here.

The $58.3 billion capped BASF has obtained a non-exclusive license from the US Broad Institute to modify crop plants to increase yield and make them resistant to disease.

I remember when BASF used to make audio cassette tapes that allowed me to tape songs from the radio. Although one more hot day like yesterday and my memory will be a blister in the sun.

With Christmas 2018 now a short memory, researchers at the University of Warwick have been experimenting with CRISPR-Cas9, proposing to use it to insert firefly genes for glowing proteins into the genomes of Christmas trees.

That means you wouldn’t need lights, the trees would naturally glow at night.

I’m dreaming of a genome Christmas.

And it seems many others have their own plans for genomes. Take the group that started a Kickstarter campaign to make bioluminescent pot plants, or Dutch artist Daan Roosegaarde who wants streetlights to glow (clearly with less electricity used).

Euro biotech Syngulon will be developing antibacterial peptides using CRISPR-Cas9.

Syngulon has been working on developing bacteriocins, molecules that are useful alternatives to antibiotics. They need much smaller quantities to have the same effect and reduce production costs and increase yield. They also help to reduce over-reliance on antibiotics.

Last year, Australia jumped on the CRISPR-CAS9 bandwagon when Australia's gene technology regulator Raj Bhula proposed reducing regulations around gene editing techniques such as CRISPR, following a 12 month technical review into the current regulations.

"With gene editing you don't always have to use genetic material from another organism, it is just editing the [existing] material within the organism," Dr Bhula said.

"All of our regulatory frameworks and laws have been established based on people putting unrelated genetic material into another organism.

"Whereas this process is just manipulation within the organism and not introducing anything foreign."

That sounds promising, especially for any Australian biotech working in this field.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.